Technology
Health
Biotechnology

Soligenix

$1.12
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.05 (4.76%) Today
+$0.02 (1.82%) As of 4:21 PM EDT after-hours

Why Robinhood?

You can buy or sell Soligenix and other stocks, options, ETFs, and crypto commission-free!

About SNGX

Soligenix, Inc. engages in the development and commercialization of products to treat rare disease. It operates through the following segments: BioTherapeutics and Vaccines/BioDefense. Read More The BioTherapeutics segment offers photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Vaccines/BioDefense segment includes active development programs for RiVax, ricin toxin vaccine candidate, OrbeShield, GI acute radiation syndrome therapeutic candidate, and SGX943, melioidosis therapeutic candidate. The company was founded in 1987 and is headquartered Princeton, NJ.

Employees
14
Headquarters
Princeton, New Jersey
Founded
1987
Market Cap
20.30M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
101.03K
High Today
$1.10
Low Today
$1.00
Open Price
$1.05
Volume
69.36K
52 Week High
$2.20
52 Week Low
$0.65

Collections

Technology
Health
Biotechnology
Therapy
2016 IPO
US
North America

SNGX Earnings

-$0.27
-$0.18
-$0.09
$0.00
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
-$0.12 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.